Article CommentaryCommentary

A Risk-Based Auditing Process for Pharmaceutical Manufacturers

Susan Vargo, Bob Dana, Vijaya Rangavajhula and Stephan Rönninger
PDA Journal of Pharmaceutical Science and Technology March 2014, 68 (2) 104-112; DOI: https://doi.org/10.5731/pdajpst.2014.00954

Article Information

vol. 68 no. 2 104-112
DOI 
https://doi.org/10.5731/pdajpst.2014.00954
PubMed 
24668599
Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Published online March 25, 2014.
Copyright & Usage 
© PDA, Inc. 2014

Author Information

  1. Susan Vargo1,
  2. Bob Dana2,
  3. Vijaya Rangavajhula3 and
  4. Stephan Rönninger4
  1. 1Amgen, Inc., Longmont, CO, USA;
  2. 2PDA, Bethesda, MD, USA;
  3. 3Divison of Acquired Immunodeficiency Syndrome, National Institutes of Health (NIH), Bethesda, MD, USA;
  4. 4Amgen (Europe) GmbH, Zug, Switzerland
  1. *Corresponding Author: Susan Vargo, Amgen, Inc., 4000 Nelson Road, M/S AC27C, Longmont, CO 80503, USA. svargo{at}amgen.com
View Full Text

Cited By...

Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
A Risk-Based Auditing Process for Pharmaceutical Manufacturers
Susan Vargo, Bob Dana, Vijaya Rangavajhula, Stephan Rönninger
PDA Journal of Pharmaceutical Science and Technology Mar 2014, 68 (2) 104-112; DOI: 10.5731/pdajpst.2014.00954
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords